Get Pediarix Schedule

Routine vaccination Prospectively: Dose 4 may be administered as early as age 12 months if at least 6 months have elapsed since dose 3. Retrospectively: A 4th dose that was inadvertently administered as early as 12 months may be counted if at least 4 months have elapsed since dose 3.

FDA licensed in 2008 as a 4-dose series in infants and children at ages 2, 4, 6, and 15 18 months. It should not be used for any dose in the primary series for children age 5 years or older or as the booster dose for children ages 4 through 6 years.

Pediarix contains DTaP, IPV, and Hep B Neither nor Pediarix should be used prior to 6 weeks of age. In general ACIP recommends the same brand of DTaP be used for all doses of the series.

of Different Vaccines If live parenteral (injected) vaccines (MMR, MMRV, varicella, zoster, and yellow fever) and live intranasal influenza vaccine (LAIV) are not administered at the same visit, they should be separated by at least 4 weeks.

PEDIARIX is approved for use as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. 6 PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th 7 birthday).

Who is eligible to get Pediarix? Pediarix is approved as a 3-dose primary series, at 2, 4, and 6 months of ages. It is licensed for children 6 weeks through 6 years of age.

Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 4 weeks (Table 3-3), to minimize the potential risk for interference.

Safety and effectiveness of in children younger than 4 years and children aged 7 to 16 years have not been evaluated. is not approved for use in persons in these age groups.

should not be given to children younger than 4 years of age or after the seventh birthday; is not licensed for more than a single dose or for primary catch-up doses. Minimum interval for valid booster dose of DTaP-IPV is six months after the last DTaP.